核苷类药物在慢性乙型病毒性肝炎中的应用  

Aplication of Nucleoside drugs in the Treatment Chronic Hepatitis B

作　　者：路显锋[1] 王晓丹[1] 冯建鹏[1] 

机构地区：[1]扬子江药业集团江苏海慈生物药业有限公司研发部,江苏泰州225321

出　　处：《医学综述》2012年第19期3226-3228,共3页Medical Recapitulate

摘　　要：慢性乙型肝炎治疗的根本目标是清除乙型肝炎病毒(HBV),阻断HBV复制,只有清除HBV才能阻止慢性乙型病毒性肝炎向肝脏失代偿、肝硬化、肝癌发展,减少并发症。国内外医学界公认的抑制乙型病毒性肝炎复制的药物主要有干扰素和核苷类似物两大类。近年来核苷类似物成为抗病毒药物的研究热点,该类药物抗HBV作用较强。现主要对拉米夫定、阿德福韦酯、恩替卡韦和替比夫定的疗效比较、联合用药、安全性等进行简要的介绍。About viral hepatitis B, the treatment goal is to clear HBV and block its replication. Only inthis way can stop the course of disease from chronic hepatitis B developing into hepatic decompensation, liver cirrhosis and liver cancer,and reduce the complications. Current treatments for Hepatitis B mostly relies on interferon and nucleoside analogs. In recent years, antiviral nucleoside analogs become the research focus, be- cause of its strong antivirus activity. Here introduces nucleoside drugs such-as lamivudine, adefovir dipivoxil, entecavir and telbivudine,from the perspective of their combination therapy, safety and effect comparison.

关 键 词：恩替卡韦 替比夫定 阿德福韦酯 拉米夫定 

分 类 号：R512.62[医药卫生—内科学]